DPX-E7 / BioVaxys - LARVOL DELTA

ANTIGEN-PROCESSING DEFECTS DO NOT FULLY EXPLAIN LIMITED CD8+ T-CELL RECOGNITION OF THE HUMAN PAPILLOMAVIRUS TYPE 16 E6(29-38) EPITOPE (IPVC 2024) - "The mechanisms underlying this remain largely unknown. Here, we performed a systematic characterisation of HPV16 E629-38 epitope presentation and compared this to the well-characterised HLA-A*02:01-restricted HPV16 E711-19 epitope... Contrary to previous studies, we did not find any evidence that the inadequate CD8+ T-cell responses unique to the HPV16 E629-38 epitope are caused by defects in the canonical antigen-processing pathway. Our future experiments aim to further explore this discrepancy to help inform the development of T-cell immunotherapies for HPV16-associated cancers."

Cervical Cancer • Oncology • Solid Tumor • CD8 • HLA-A • TAP1

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2 | N=11 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Feb 2023

Trial completion • Trial completion date • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • HLA-A

CRTE7A2-01: A HPV-16 E711-19 Specific TCR Targeting HPV-Related Cancers (ASGCT 2023) - P1 | "Furthermore, CRTE7A2 shows excellent safety in vivo.We are now conducting a single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D (NCT05122221)."

Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Infectious Disease • Oncology • Solid Tumor • HLA-A • IFNG

Discovery of TSC-200-A02: A Natural HPV16 E7-Specific TCR-T Cell Therapy Candidate for the Treatment of HPV-Positive Solid Tumors (ASGCT 2022) - "Using TScan’s proprietary ReceptorScan platform, we discovered 453 putative HPV16 E711-19-specific TCRs by screening 681 million naïve CD8+ T cells from 15 unique healthy donors. We have advanced the resulting autologous TCR-T cell therapy candidate, TSC-200-A02, to IND-enabling studies. These results validate the use of ReceptorScan, in conjunction with SafetyScan, as a way to rapidly identify naturally occurring, high affinity TCRs that are suitable for clinical development."

Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • CD4 • CD8 • HLA-A • TGFBR2

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2 | N=11 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: May 2023 ➔ Dec 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • HLA-A

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2; N=11; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial primary completion date • Anal Carcinoma • Cervical Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • HLA-A

IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results (Businesswire) - “Maveropepimut-S - Q1 2021: Finalization of clinical protocol and collaboration agreement with partner for Phase 2B clinical trial in r/r DLBCL; Q2 2021: Translational and Biomarker analysis update for Ovarian cancer DeCidE1 trial; Q2 2021: Initiation of r/r DLBCL Phase 2B trial; H2 2021: Meeting with the FDA and final clinical design for a Phase 2B study in Advanced Recurrent Ovarian Cancer; H2 2021: Updated results for the basket trial. DPX-SurMAGE - H2 2021: Initiation of a Phase 1 clinical study in bladder cancer.”

Clinical protocol • FDA event • New P1 trial • New P2b trial • Bladder Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2; N=11; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Recruiting ➔ Active, not recruiting; N=44 ➔ 11

Clinical • Enrollment change • Enrollment closed

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2; N=44; Recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: Dec 2019 ➔ Dec 2020

Clinical • Trial primary completion date

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov) - P1/2; N=44; Recruiting; Sponsor: Dana-Farber Cancer Institute; Trial primary completion date: May 2019 ➔ Dec 2019

Clinical • Trial primary completion date